Deltec Asset Management LLC trimmed its stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 74.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,700 shares of the biopharmaceutical company’s stock after selling 100,000 shares during the period. Deltec Asset Management LLC’s holdings in Horizon Pharma were worth $492,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in HZNP. Paulson & CO. Inc. purchased a new stake in shares of Horizon Pharma during the second quarter valued at $58,584,000. Dimensional Fund Advisors LP lifted its holdings in shares of Horizon Pharma by 119.4% during the second quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after purchasing an additional 3,409,411 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Horizon Pharma by 419.1% during the third quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock valued at $26,979,000 after purchasing an additional 1,717,841 shares during the last quarter. State Street Corp lifted its holdings in shares of Horizon Pharma by 12.0% during the second quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock valued at $58,241,000 after purchasing an additional 524,187 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Horizon Pharma by 1,865.4% during the third quarter. Principal Financial Group Inc. now owns 399,132 shares of the biopharmaceutical company’s stock valued at $5,060,000 after purchasing an additional 378,824 shares during the last quarter. 85.95% of the stock is owned by institutional investors and hedge funds.
HZNP has been the subject of several analyst reports. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the company a “buy” rating in a report on Wednesday, December 27th. BidaskClub raised Horizon Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. UBS Group set a $20.00 target price on Horizon Pharma and gave the company a “buy” rating in a report on Thursday, November 30th. Jefferies Group upped their target price on Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 target price on shares of Horizon Pharma in a report on Sunday, October 22nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. Horizon Pharma presently has an average rating of “Buy” and a consensus price target of $19.25.
Horizon Pharma PLC (HZNP) opened at $13.82 on Tuesday. The firm has a market capitalization of $2,368.15, a price-to-earnings ratio of -4.53, a P/E/G ratio of 0.68 and a beta of 1.35. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $17.69. The company has a current ratio of 1.64, a quick ratio of 1.52 and a debt-to-equity ratio of 1.89.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. Horizon Pharma’s quarterly revenue was up 30.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.70 earnings per share. equities analysts predict that Horizon Pharma PLC will post 0.72 EPS for the current fiscal year.
Horizon Pharma Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.